While the current study is focused on the effect and mechanism of KAT2B in cholangiocarcinoma, it remains to be determined whether the KAT2B-NF2-YAP signaling pathway identified in CCA may also be applicable to other cancers. This evidence concerns the gene KAT2B and cancer.